The MEA stroke diagnostic and therapeutic market is projected to grow from USD 6.74 billion in 2025 to USD 14.96 billion by 2035, at a CAGR of 8.3%, fueled by rising stroke prevalence, improved healthcare infrastructure, and increasing adoption of advanced diagnostic and therapeutic solutions.

MEA Stroke Diagnostic and Therapeutic Market Statical Scope

Growing consumer awareness and ongoing advancements in stroke diagnostic and therapeutic technologies are propelling market growth in the Middle East and Africa. Major pharmaceutical and device manufacturers are making substantial investments in research and development to discover effective solutions for stroke diagnosis and treatment.

Increased healthcare expenditures, developing infrastructure, and expanded insurance coverage are further contributing to this regional growth. The rise in healthcare investments, governmental efforts to enhance early detection and treatment, and the increasing burden of chronic diseases such as hypertension and diabetes are intensifying the need for rapid and accurate stroke diagnosis.

MEA Stroke Diagnostic and Therapeutic Market Share, By By Country, 2025 (%)

• Saudi Arabia- In Saudi Arabia, the incidence of stroke is rising within an evolving demographic and healthcare system context. Saudi Arabia's Vision 2030 and the Health Sector Transformation Program underscore a commitment to value-based care and integrated clinical pathways, boosting growth.

MEA Stroke Diagnostic and Therapeutic Market Share, By Type, 2025 (%)

• Diagnostics- Diagnostics dominate the segment, with a share of 56.5%, driven by the critical need for early stroke detection, increasing adoption of advanced imaging technologies, and growing emphasis on timely diagnosis.
• Therapeutics- Therapeutics hold a significant portion of 43.5%, supported by rising demand for effective treatment options, including thrombolysis and surgical interventions for stroke management.

MEA Stroke Diagnostic and Therapeutic Market Share, By Application, 2025 (%)

• Ischemic Stroke- Ischemic Stroke leads the segment, with a share of 63%, driven by its higher prevalence compared to hemorrhagic stroke and increasing demand for rapid diagnostic and treatment solutions
• Hemorrhagic Stroke- Hemorrhagic Stroke accounts for a notable share, with a share of 37%, supported by the need for specialized treatment approaches despite lower incidence rates compared to ischemic stroke.

Top Companies in the MEA Stroke Diagnostic and Therapeutic Market

• Neural Analytics
• Cordis Corporation
• Cerebrotech Medical Systems, Inc.
• Koninklijke Philips N.V.
• Medtronic plc.
• Boston Scientific Corporation
• GE Healthcare
• Medfield Diagnostics
• Samsung Neurologica
• NIRX
• Gowerlabs
• Siemens AG
• Genentech Inc.
• Merck & Co., Inc.
• Hyperfine MRI
• Stryker Corporation
• Abbott Laboratories

Segments Covered in the Report

By Type

• Diagnostics
• Therapeutics

By Application

• Haemorrhagic Stroke
• Ischemic Stroke